Abaloparatide Research: What 390 Studies Show (2026) | RetatrutideCompare

Abaloparatide — 390 studies indexed on PubMed. Selective PTH1R agonist with bias toward the transient (RG) receptor conformation, producing more anabolic, less resorptive bone signaling than Teriparatide. Half-life: ~1.7 hours. FDA status: FDA-approved (2017).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Abaloparatide?

There are approximately 390 studies indexed on PubMed that mention Abaloparatide (Tymlos, BA058), based on a search last updated 2026-06-18.

Is Abaloparatide FDA-approved?

FDA status: FDA-approved (2017).

How does Abaloparatide work?

Selective PTH1R agonist with bias toward the transient (RG) receptor conformation, producing more anabolic, less resorptive bone signaling than Teriparatide.

Selective PTH1R agonist with bias toward the transient (RG) receptor conformation, producing more anabolic, less resorptive bone signaling than Teriparatide.

Reference facts

Also known as
Tymlos, BA058
Category
Bone & Calcium
Mechanism of action
Selective PTH1R agonist with bias toward the transient (RG) receptor conformation, producing more anabolic, less resorptive bone signaling than Teriparatide.
Targets
PTH1R (RG-biased)
Indications under research or approved
Postmenopausal osteoporosis (high fracture risk)
Regulatory status (reference entry)
FDA-approved (2017)
Half-life
~1.7 hours
Sequence
AVSEHQLLHDKGKSIQDLRRRELLEKLLAKKLAH
Sequence notes
34-residue PTHrP analog with multiple substitutions for selective PTH1R RG conformation activation.
Molecular weight (Da)
3961
Originator / sponsor
Radius Health
First reported
2008

Primary References

Explore research articles about Abaloparatide

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.